{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T16:45:42Z","timestamp":1726505142878},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.pnpbp.2011.08.001","type":"journal-article","created":{"date-parts":[[2011,8,8]],"date-time":"2011-08-08T10:01:47Z","timestamp":1312797707000},"page":"213-219","source":"Crossref","is-referenced-by-count":2,"title":["Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients"],"prefix":"10.1016","volume":"36","author":[{"given":"Andreas","family":"Windemuth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Goethe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold I.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Susce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohan","family":"Kocherla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kali","family":"Bogaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore R.","family":"Holford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard L.","family":"Seip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gualberto","family":"Rua\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2011.08.001_bb0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/mp.2010.14","article-title":"Genome wide pharmacogenomic study of metabolic side effects to antipsychotic drugs","volume":"16","author":"Adkins","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0010","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","author":"Anon","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0015","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jpsychires.2010.02.002","article-title":"Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort","volume":"44","author":"Athanasiu","year":"2010","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0020","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1001\/jama.292.23.2833-a","article-title":"Antidepressants and the risk of suicidal behaviors","volume":"292","author":"Barbui","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1472-8206.2009.00751.x","article-title":"Pharmacogenetic of response efficacy to antipsychotics in schizophrenia: pharmacodynamic aspects. Review and implications for clinical research","volume":"24","author":"Blanc","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0030","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1751-7176.2010.00293.x","article-title":"Metabolic abnormalities in adult and geriatric major depression with and without comorbid dementia","volume":"12","author":"Blank","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0035","unstructured":"Centers for Disease Control and Prevention (CDC): National Center for Health statistics (NCHS) (2008) National health and examination survey. U.S. Department of Health and Human Services"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0040","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.v67n0408","article-title":"Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs","volume":"67","author":"Correll","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0045","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2007.05.020","volume":"96","author":"de Leon","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation","volume":"66","author":"de Leon","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2007.01.015","article-title":"A clinical study of the association of antipsychotics with hyperlipidemia","volume":"92","author":"de Leon","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.schres.2007.10.003","article-title":"Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels","volume":"98","author":"de Leon","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0070","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2009.09.038","article-title":"Acetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels","volume":"115","author":"Diaz","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0075","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.cll.2010.07.010","article-title":"Pharmacogenetics and schizophrenia","volume":"30","author":"Foster","year":"2010","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0080","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4088\/JCP.v66n0619","article-title":"Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues","volume":"66","author":"Franciosi","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0085","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1126\/science.1141634","article-title":"A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity","volume":"316","author":"Frayling","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/JCP.v68n0103","article-title":"Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review","volume":"68","author":"Goethe","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0095","unstructured":"Goethe, J. W., Szarek, B. L., Blank, K., and Caley, C. F. (2009a) Metabolic Syndrome in patients with major depressive disorder: Associated risk factors. Psychiatric Times"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0100","series-title":"Metabolic Effects of Psychotropic Drugs","first-page":"90","article-title":"Metabolic syndrome in psychiatric inpatients treated for depression","author":"Goethe","year":"2009"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/14622416.8.4.311","article-title":"Primum non nocere: adverse drug events must be taken seriously","volume":"8","author":"Gurwitz","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1517\/14728222.9.2.267","article-title":"Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition","volume":"9","author":"Harwood","year":"2005","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0115","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2337\/diacare.28.9.2289","article-title":"The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"28","author":"Kahn","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0120","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MJT.0b013e318197eadf","article-title":"Rapidly worsening hypertriglyceridemia during treatment with risperidone","volume":"17","author":"Kohen","year":"2010","journal-title":"Am J Ther"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0125","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1176\/appi.ajp.163.7.1273","article-title":"Prevalence of the metabolic syndrome among patients receiving clozapine","volume":"163","author":"Lamberti","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0130","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/dmrr.1066","article-title":"A genetic variation in the fat mass- and obesity-associated gene is associated with obesity and newly diagnosed type 2 diabetes in a Chinese population","volume":"26","author":"Li","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0135","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/ng.140","article-title":"Common variants near MC4R are associated with fat mass, weight and risk of obesity","volume":"40","author":"Loos","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ng0208-129","article-title":"A treasure trove for lipoprotein biology","volume":"40","author":"Lusis","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.bp.106.031716","article-title":"Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community","volume":"191","author":"Mackin","year":"2007","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0155","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00004714-200108000-00003","article-title":"Novel antipsychotics and severe hyperlipidemia","volume":"21","author":"Meyer","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00131746-200601000-00002","article-title":"Prevalence of the metabolic syndrome in veterans with schizophrenia","volume":"12","author":"Meyer","year":"2006","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0165","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.pnpbp.2010.11.037","article-title":"Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit\/hyperactivity disorder","volume":"35","author":"Mick","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.pnpbp.2011.08.001_bb0170","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0175","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ng.361","article-title":"Genome-wide association study identifies eight loci associated with blood pressure","volume":"41","author":"Newton-Cheh","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0180","unstructured":"NIMHS (2009) National Institute of Mental Health Statistics. U.S. Department of Health and Human Services."},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0185","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1176\/appi.ajp.163.10.1821","article-title":"Hyperlipidemia following treatment with antipsychotic medications","volume":"163","author":"Olfson","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0190","first-page":"112","article-title":"Performance of the CardioChek PA and Cholestech LDX point-of-care analysers compared to clinical diagnostic laboratory methods for the measurement of lipids","volume":"16","author":"Panz","year":"2005","journal-title":"Cardiovasc J S Afr"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0195","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2337\/db09-0653","article-title":"A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose","volume":"59","author":"Paterson","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0200","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/sj.mp.4001944","article-title":"Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients","volume":"12","author":"Rua\u00f1o","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0205","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1126\/science.1142382","article-title":"A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants","volume":"316","author":"Scott","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0210","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1176\/appi.ajp.159.4.561","article-title":"Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia","volume":"159","author":"Sernyak","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0215","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nature05616","article-title":"A genome-wide association study identifies novel risk loci for type 2 diabetes","volume":"445","author":"Sladek","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0220","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2571","article-title":"Schizophrenia therapy: beyond atypical antipsychotics","volume":"7","author":"Snyder","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0225","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2337\/db08-1660","article-title":"G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans","volume":"58","author":"Sparso","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4088\/JCP.v66n0203","article-title":"Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey","volume":"66","author":"Susce","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0235","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2008.12.003","article-title":"Assessing metabolic syndrome: waist circumference versus BMI","volume":"108","author":"Szarek","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0240","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1176\/appi.ajp.2009.09070932","article-title":"Genome-wide pharmacogenetics of antidepressant response in the GENDEP project","volume":"167","author":"Uher","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0245","unstructured":"Wampers M, Hanssens L, van WR, Heald A, Collette J, Peuskens J, et al. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Eur Neuropsychopharmacol in press."},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0250","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.76","article-title":"Newly identified loci that influence lipid concentrations and risk of coronary artery disease","volume":"40","author":"Willer","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0255","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng.287","article-title":"Six new loci associated with body mass index highlight a neuronal influence on body weight regulation","volume":"41","author":"Willer","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.pnpbp.2011.08.001_bb0260","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1126\/science.1142364","article-title":"Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes","volume":"316","author":"Zeggini","year":"2007","journal-title":"Science"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461100248X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461100248X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T19:19:38Z","timestamp":1712690378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027858461100248X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S027858461100248X"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2011.08.001","relation":{},"ISSN":["0278-5846"],"issn-type":[{"type":"print","value":"0278-5846"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}